Article info

Download PDFPDF

Original research
Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Authors

  1. Correspondence to Dr Erika J Lampert; lampere{at}ccf.org
View Full Text

Citation

Lampert EJ, Cimino-Mathews A, Lee JS, et al
Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Publication history

  • Accepted June 16, 2020
  • First published July 23, 2020.
Online issue publication 
July 23, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.